Biopharma/Biotech Analyst Chen and Biotech Analyst Watsek, along with Professor Okada of the University of California-San Francisco, Professor of Hematology Diamond at City of Hope and Randall Hyer, former SVP at Moderna, discuss the opportunity for personalized cancers vaccines (relevant companies MRK, MRNA, BNTX, GRTS) on an Analyst/Industry conference call to be held on April 20 at 1 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck, Eisai colorectal cancer study did not meet statistical significance
- Merck, Eisai discontinuing Phase 3 melanoma combination study
- Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Merck, Proxygen enter collaboration, license agreement